There are 2949 resources available
IO combinations in first-line advanced HCC: Current evidence and ongoing trials
Presenter: Peter Galle
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations early or intermediate-stage HCC: Current evidence and ongoing trials
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Putting it all together: Case discussions
Presenter: Bruno Sangro
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Summary, final thoughts, and audience question and answer session
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Welcome and introduction
Presenter: Tanja Cufer
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma
Presenter: Silvia Novello
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Uncommon EGFR mutations
Presenter: Xiuning Le
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
The Future of NSCLC
Presenter: Melissa Johnson
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Key insights and closing remarks
Presenter: Tanja Cufer
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Challenges in the treatment of prostate cancer
Presenter: Daniel George
Session: Pfizer Oncology - Building a new paradigm in prostate cancer
Resources:
Webcast